期刊文献+

3种不同C反应蛋白测定试剂盒的性能评价 被引量:2

Performance evaluation of 3 different C-reactive protein assay kits
下载PDF
导出
摘要 目的对A、B、C3种不同C-反应蛋白(CRP)试剂盒在全自动生化分析仪上进行测定性能评价。方法 A试剂为普通免疫透射比浊法CRP,B试剂为高敏CRP(hs-CRP),C试剂为宽范围hs-CRP。检测3种试剂的测定范围、精密度、抗干扰能力和临床标本测定结果相关性。结果测定范围:A试剂为6.0~160.0mg/L,B试剂为0.1~20.0mg/L,C试剂为0.1~320.0mg/L;B、C试剂精密度优于A试剂;B、C试剂均有较好的重复性和稳定性;C试剂抗脂血和溶血能力强。结论 C试剂是根据免疫增强透射比浊法的原理,采用大小不同的2种胶乳颗粒为载体,因此同时具备高敏感性和宽测定范围的特点,更具有临床应用价值。 Objective To make performance evaluation of 3 different C-reactive protein(CRP) assay kits,that was A,B and C,in automatic biochemical analyzer.Methods A reagent was ordinary CRP using immune enhancing transmission turbidity method,B reagent was high sensitivity CRP(hs-CRP),and C reagent was wide range of hs-CRP.The determination ranges,degree of precision,ability of anti-interference and correlation of determination results of clinical specimens were detected.Results Determination range of A reagent was 6.0~160.0mg/L,and that of B reagent and C reagent was 0.1~20.0mg/L and 0.1~320.0mg/L respectively. The degree of precision of B reagent and C reagent was better than that of A reagent. B reagent and C reagent were all of good repeatability and stability.C reagent had strong action on anti-lipohemia and anti-hemolysis.Conclusion According to the principle of immune enhancing transmission turbidity method,C reagent adopts 2 kinds of latex particles,which are of different sizes,as the carrier,so it has both the features of high sensitivity and wide determination range,and it is of more clinical application value.
作者 黄瑞英
出处 《临床合理用药杂志》 2010年第24期3-5,共3页 Chinese Journal of Clinical Rational Drug Use
关键词 C反应蛋白 高敏C反应蛋白 宽范围C反应蛋白 免疫增强透射比浊法 性能 CRP hs-CRP wcCRP Immune enhancing transmission turbidity Performance
  • 相关文献

参考文献7

二级参考文献18

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 2付文金 李毅.CRP的检测在AS类疾病中的应用进展[J].中国医学文摘,2002,23(1):105-107.
  • 3Anderson JL, Carlquist JF. Muhlestein JB, et al. Evaluation of C-reactive protein, an inflammatory marker. and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol, 1998,32:35-41.
  • 4Zhu J, Quyyumi AA, Norman JE, et al Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J Am Coll Cardiol,1999,34:1738-1743.
  • 5Muhlestein JB, Horne BD, Carlquist JF, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation, 2000,102:1917-1923.
  • 6Biasucci LM.Liuzzo G,Grillo RL. et al. Elevated revels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation,1999,99:855-860.
  • 7Cavusoglu y, Gorenek B, Alpsoy S, et al Evaluation of C-reactive protein, fibrinogen and antithrombin- M as risk factors for coronary artery disease. Isr Med Assoc J,2001,3:13-16.
  • 8Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronarysyndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998, 31:1460-1465.
  • 9Zhu J, Quyyumi AA, Norman JE, et al. Effects of total pathogen burden on coronary artery disease risk and Creactive protein levels. Am J Cardiol,2000,85:140-146.
  • 10Torzewski J, Torzewski M, Bowyer DE, et al C-reactive protein frequently coloealizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol, 1998,18:1386-1392.

共引文献265

同被引文献11

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部